Tag: tumor microenvironment

Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors

EAGAN, MN — April 16, 2018 — Biothera Pharmaceuticals, Inc. today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biothera’s Imprime PGG with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck (known as MSD outside the United States and Canada).  These data provide the first evidence in human clinical trials that Imprime PGG-based therapy can activate the immune system...

Read More


Biothera Pharmaceuticals and Merck Further Expand Research Collaboration to Include Phase 2 Clinical Trial in Head and Neck Cancer

Trial to Test Combination of Biothera’s Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab) EAGAN, MN — December 5, 2016 — Biothera Pharmaceuticals, Inc. today announced an expansion of its research collaboration with Merck (known as MSD outside the United States and Canada) to include a Phase 2 clinical study investigating Biothera’s Imprime PGG in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in second- and third-line patients...

Read More


Biothera Pharmaceuticals Preclinical Data Further Validate Mechanism of its Phase 2 Cancer Immunotherapy, Imprime PGG

3 Poster Presentations Scheduled for Society for Immunotherapy of Cancer Annual Meeting EAGAN, MN — November 11, 2016 — Biothera Pharmaceuticals, Inc. will present new preclinical data today that further validate the ability of its Phase 2 cancer immunotherapy drug Imprime PGG to induce coordinated innate and adaptive immune responses that may enhance the efficacy of checkpoint inhibitor therapies. The data will be highlighted in three...

Read More


Clinical Data Support Mechanism of Action and Patient Selection Biomarker for Imprime PGG, Biothera Pharmaceutical’s Phase 2 Cancer Immunotherapy

Clinical findings presented at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference EAGAN, MN — September 27, 2016 — Biothera Pharmaceuticals, Inc. today announced the presentation of clinical data demonstrating the mechanism of action of Imprime PGG, the Company’s Phase 2 cancer immunotherapy drug, in healthy human volunteers. These are the first data to show that when administered intravenously to healthy human subjects, Imprime PGG drives the immunopharmacodynamic...

Read More


Biothera Pharmaceuticals Presents New Cancer Immunotherapy Research at the 2016 American Association for Cancer Research (AACR) Annual Meeting

EAGAN, MN — April 18, 2016 — Biothera Pharmaceuticals, Inc. today announced research providing new insights into the ability of the Company’s Phase 2 cancer immunotherapy to coordinate innate and adaptive immune responses and enhance the effectiveness of combination therapies. The findings were presented today at the AACR annual meeting, which is taking place in New Orleans, LA, April 16-20, 2016. The company is presenting...

Read More


Biothera to Present Three Abstracts at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

EAGAN, MN — November 2, 2015 — Biothera, a clinical stage biotechnology company pioneering the development of immune potentiators known as PAMPs for cancer immunotherapy, will present three abstracts at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place November 5–9 at the Hynes Convention Center in Boston. PAMPs (Pathogen Associated Molecular Patterns) serve as critical recognition signals...

Read More


Replay Available of Webcast Featuring Biothera Pharmaceutical Technology

EAGAN, MN — July 21, 2015 — Biothera Pharmaceutical Senior Vice President of Research Jeremy Graff, Ph.D. explained new research during a webinar today that shows how Imprime PGG targets multiple cells types that orchestrate a coordinated anti-tumor response involving both the innate and adaptive immune system. The webinar was part of the Biopharma Dealmarkers series hosted by Nature.com. Click here to for a replay of the webinar. Biothera...

Read More


Biothera to Participate in Webcast on Advances in Cancer Immunotherapy

EAGAN, MN — June 18, 2015 — Jeremy Graff, Ph.D., Senior Vice President, Pharmaceutical Research for Biothera, will participate in a BioPharma Dealmakers webcast featuring four companies developing cancer immunotherapies. The webcast is scheduled for 11:00 am ET on July 21. Webcast registration. The webcast will explore some of the challenges and opportunities of technologies at the cutting edge of cancer immunotherapy. Participants will learn...

Read More


Biothera to Present Additional Data to the American Association of Immunologists on Imprime PGG’s Potential to Alleviate Tumor-mediated Immunosuppression

NEW ORLEANS — May 8, 2015 — Additional data showing Biothera’s investigational cancer immunotherapy Imprime PGG can alleviate tumor-mediated immunosuppression and potentially strengthen the body’s ability to recognize and kill tumor cells will be presented on Sunday at the American Association of Immunologists (AAI) annual meeting. Earlier this month at the American Association for Cancer Research, Biothera presented new research supporting the potential of Imprime...

Read More


Biothera’s Investigational Cancer Immunotherapy Alleviates Immune Suppression by Regulatory T Cells, Enabling CD4 and CD8 T Cell Proliferation, Study Finds

New Data Presented at the American Association for Cancer Research Annual Meeting PHILADELPHIA — April 22, 2015 — Biothera’s investigational cancer immunotherapy Imprime PGG enhances the function and proliferation of T cells that play a critical role in the fight against cancer, according to new data presented today at the American Association for Cancer Research (AACR) annual meeting. “Cancer can create an immunosuppressive environment that...

Read More



Page 1 of 212